Key Takeaways:
- Neuron Guard has developed the standard of care for Targeted Temperature Management (TTM) therapy.
- The device can be used in any circumstance and allows the user to fully manage the temperature of the patient, either warming or cooling as necessary.
- Neuron Guard’s vision is to have their device in every public place, much like the Automatic External Defibrillator (AED).
- The startup is seeking to raise 2.5M€ to complete the pre-industrialization, design and construction of the human device for the pilot trial, finalize the regulatory clearance, and launch it into the market in 2019.
Introduction
Italian startup Neuron Guard is a groundbreaker in the field of biotechnology, healthcare, and medical devices. The company focuses on managing the temperature of brain damage patients and is championing the cause of Targeted Temperature Management (TTM) therapy. With a life-saving device that has the potential to revolutionize the standard of care, the startup is committed to improving the safety of patients globally. Also, Neuron Guard was recognized as the best European startup in the health category, under the EU’s Startup Europe Awards in 2017.
According to data from the World Health Organisation, every seven seconds, a person suffers from acute brain damage, primarily due to Cardiovascular Diseases (CVD) and Traumatic Brain Injury (TBI). These causes have been recorded as the most prevalent and costly killers for over the last 15 years. Neuron Guard strives to address this need with its novel TTM therapy device.
What sets Neuron Guard Apart?
The standout feature of Neuron Guard is their unique TTM device, a system made up of a therapeutic collar powered by a smart control unit. The collar effortlessly transforms the neck into a natural heat exchanger, leveraging the physiological and anatomical characteristics of the human body. This empowers the device not only to act on brain tissue effectively but also function as a total body temperature adjusting device when required. The device can be used anywhere, regardless of the environment, making it an essential tool for first responders or caregivers in emergency situations.
Currently patented in Italy, America and China, Neuron Guard’s device is both effective and versatile. By collecting data during treatment and transmitting it to the Emergency Response System, the technology allows for responsive and efficient patient care. Additionally, the startup has a vision that its device, much like existing Automatic External Defibrillators (AED), will become commonplace in public places, helping to facilitate quick response in emergency situations.
Looking to the Future
Neuron Guard’s innovative approach to TTM therapy definitely positions the startup as a trailblazer in the biotech and healthcare industries. The company’s vision of having their device on hand in various public places showcases the potential to change the way society responds to emergency situations involving brain injuries and other conditions requiring temperature management. Ultimately, improving patient safety and reducing the costs of chronic care are at the heart of Neuron Guard’s mission.
To achieve these goals, the company is seeking to raise 2.5M€ to finalize the design and construction of the human device for a pilot trial. This will lead to regulatory clearance and hopefully a market launch in 2019. Built with continuous innovation, it seems clear that Targeted Temperature Management (TTM) therapy and Neuron Guard’s specialized device may indeed be the future of brain injury treatment. For more while we wait for further updates on the company’s progress:
Visit: Neuron Guard’s website
Follow: Neuron Guard on Twitter
Like: Neuron Guard on Facebook
Connect: Neuron Guard on LinkedIn
Want to amplify your startup’s story? EU Startup News is your launchpad to reach startup founders, investors, and C-level execs across Europe. Discover our tailored promotional strategies such as Sponsored Articles and Partnerships. Click here to learn more or contact us directly at [email protected]. Join us, and let’s make your startup the talk of Europe!
